JAMA Editors' Summary Tumor Debulking in Metastatic Colorectal Cancer, Physical Restraints in the ICU, Insulin Costs for Medicare Beneficiaries, and more
Mar 20, 2026
Discussion of a trial showing no survival benefit and more harm from routine tumor debulking in metastatic colorectal cancer. A randomized ICU study comparing low versus high use of physical restraints and implications for individualized restraint practice. Analysis of declining insulin out-of-pocket costs for Medicare Part D enrollees after policy changes. Brief takes on FDA transparency, AI in residency applications, and US life expectancy debates.
AI Snips
Chapters
Transcript
Episode notes
Tumor Debulking Adds Risk Without Survival Benefit
- Tumor debulking plus chemotherapy did not improve overall survival for multi-organ metastatic colorectal cancer patients compared with chemotherapy alone.
- ORCESTRA Phase III trial in the Netherlands and UK (n≈400) found median survival 30 vs 27.5 months and higher serious adverse events (53% vs 39%).
No Clear Benefit From Routine ICU Wrist Restraints
- Restrictive versus liberal wrist restraints for mechanically ventilated ICU patients showed no clear benefit for days alive and free from delirium or coma.
- R2-D2 trial (n=405) found median 6.67 vs 6.3 days and similar self-extubation and 90-day mortality rates.
Individualize Restraint Decisions In The ICU
- Avoid routine restraints; individualize decisions and minimize both physical and chemical restraint in ICU care.
- Editorial urges clinicians to weigh harms, patient circumstances, and local resources when deciding on restraint use.